Integra LifeSciences Holdings Corp. (IART) saw its stock surge 5.44% in pre-market trading on Tuesday, following the release of its fourth-quarter and full-year 2024 financial results.
The medical device maker reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share (EPS) of $0.97, surpassing analysts' estimates of $0.86. This strong performance was driven by robust demand for the company's differentiated portfolio of leading brands.
While revenue for the quarter fell slightly short of expectations at $442.65 million versus the estimated $445.15 million, the company provided an optimistic outlook for the fiscal year 2025. Integra LifeSciences expects revenue to be in the range of $1.65 billion to $1.72 billion, representing reported growth of 2.4% to 6.5% and organic growth of 1.0% to 5.0%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.